MDSpire - Takeaway
From the Journals
Clinical Guidelines

ASH 2025: Myelofibrosis Roundup

For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being pa...

Share

  • 1

    Ruxolitinib is the standard initial treatment for myelofibrosis.

  • 2

    Combination therapy with pelabresib shows promising results.

  • 3

    Elritercept aids in anemia management associated with MF.

  • 4

    Real-world studies show long-term effectiveness of ruxolitinib.

  • 5

    Stem cell transplant is the only curative option for high-risk patients.

Original Source(s)

ASH 2025: Myelofibrosis Roundup

  • by Caroline Helwick

  • March 24, 2026

Related Content

Dynamic, Accessible Risk Stratification Tool Created for Smoldering Multiple Myeloma

Researchers have developed a dynamic risk stratification tool for patients with smoldering multiple myeloma to predict their chance of progression to active multiple myeloma. The tool, called Precurso...

ASH 2025: Myelofibrosis Roundup

For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being pa...

POEMS Syndrome: Diagnostic Clues From Neuropathy to Bone Marrow Findings

POEMS syndrome is a poorly understood and complex paraneoplastic plasma cell disorder characterized by peripheral neuropathy and multisystem involvement, including organomegaly, endocrinopathy, monocl...